Abstract:
PURPOSE OF REVIEW:Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges encountered in day-to-day clinical practice. RECENT FINDINGS:Inhibitors of the PD-1/PD-L1 axis are considerably less toxic than the anti-CTLA-4 antibody ipilimumab. The combination of ipilimumab and anti-PD-1 agents is being trialled in multiple malignancies and is associated with increased toxicity. There is accumulating evidence suggesting a potential correlation between a subset of toxicities and clinical benefit in several tumour types, although conflicting data exists. Retrospective series have shown that anti-PD-1 can be safely administered to patients with prior high-grade toxicity from ipilimumab or combination immunotherapy. The management of checkpoint inhibitor toxicity is complex and requires collaboration with our subspecialty colleagues. Identifying predictive biomarkers of both efficacy and toxicity would likely help guide treatment decisions, and should be a research priority in the years ahead.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Palmieri DJ,Carlino MSdoi
10.1007/s11912-018-0718-6subject
Has Abstractpub_date
2018-07-31 00:00:00pages
72issue
9eissn
1523-3790issn
1534-6269pii
10.1007/s11912-018-0718-6journal_volume
20pub_type
杂志文章,评审abstract:PURPOSE OF REVIEW:Opioids are the only class of drug with the proven ability to control severe pain. The introduction of stringent opioid prescribing restrictions has inevitably impacted upon the ability of those prescribing opioids for advanced life-limited disease to practice as previously and could limit the supply ...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-020-0900-5
更新日期:2020-03-13 00:00:00
abstract::There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-009-0007-5
更新日期:2009-01-01 00:00:00
abstract:PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-018-0694-x
更新日期:2018-04-11 00:00:00
abstract::Overall survival for patients with squamous cell carcinoma of the head and neck (SCCHN) has not improved appreciably over the past few decades. Because standard treatments have not controlled this disease with sufficiently high success rates, novel therapeutic approaches, such as immunotherapy, are under investigation...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-008-0025-8
更新日期:2008-03-01 00:00:00
abstract::Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-006-0016-6
更新日期:2006-05-01 00:00:00
abstract:PURPOSE OF REVIEW:We aim to summarise the available evidence on systemic therapies for advanced anal cancer. RECENT FINDINGS:There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, e...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-018-0698-6
更新日期:2018-05-04 00:00:00
abstract::Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. ...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-002-0079-y
更新日期:2002-03-01 00:00:00
abstract::Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/BF02951428
更新日期:2007-01-01 00:00:00
abstract::Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor pr...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-018-0680-3
更新日期:2018-04-02 00:00:00
abstract::Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, we...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-015-0453-1
更新日期:2015-07-01 00:00:00
abstract::Lung cancer is the most common cause of cancer death worldwide. The overall 5-year survival rate remains disappointing at 14% or less. Several clinician- and community-based interventions show promise for reducing lung cancer incidence through prevention and smoking cessation. However, long-term heavy smokers retain a...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-002-0060-9
更新日期:2002-11-01 00:00:00
abstract::In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-000-0058-0
更新日期:2000-09-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma, comprising approximately 6-8% of all non-Hodgkin lymphomas. MCL is biologically and clinically heterogeneous, and there is no standard treatment for MCL. Although untreated MCL often responds well to frontline combination chemotherapy, relapsed, re...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-015-0460-2
更新日期:2015-08-01 00:00:00
abstract::Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vinc...
journal_title:Current oncology reports
pub_type: 杂志文章
doi:10.1007/s11912-012-0281-5
更新日期:2013-02-01 00:00:00
abstract::Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described. The KIT gene is commonly mutated, causing constitutive activation of the protein and a...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-003-0068-9
更新日期:2003-07-01 00:00:00
abstract::Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consiste...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-000-0016-x
更新日期:2000-01-01 00:00:00
abstract::Electronic data sharing is a critical, but underappreciated, requirement for modern medical informatics systems. This capability is facilitated by acquisition of structured clinical data, but optimized only if this data is stored and transmitted using standardized representations. Most electronic medical record and cl...
journal_title:Current oncology reports
pub_type: 杂志文章
doi:10.1007/s11912-012-0271-7
更新日期:2012-12-01 00:00:00
abstract::The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical tr...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-996-0008-6
更新日期:2004-01-01 00:00:00
abstract::Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands. Experimental data further support this hypothesis....
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-000-0090-0
更新日期:2000-03-01 00:00:00
abstract::Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic-pituitary-gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol a...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-014-0378-0
更新日期:2014-04-01 00:00:00
abstract::HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive res...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-001-0073-9
更新日期:2001-11-01 00:00:00
abstract:PURPOSE OF REVIEW:Patients with cancer have an elevated risk of cardiovascular disease. This review describes the cardiovascular risks of different cancer therapies and the evidence for cardioprotective strategies. RECENT FINDINGS:Recent studies have provided additional support for the safety and efficacy of dexrazoxa...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-020-00923-w
更新日期:2020-06-20 00:00:00
abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-002-0039-6
更新日期:2002-09-01 00:00:00
abstract:PURPOSE OF REVIEW:The calculation of noncancer-specific life expectancy can guide shared decision-making and avoid over- and undertreatment in older adults with cancer. Several factors determine life expectancy, including socio-demographic background, comorbidities, physical performance, and geriatric assessment variab...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-019-0821-3
更新日期:2019-06-25 00:00:00
abstract::Pediatric medicine is moving toward a greater appreciation that the delivery of quality medical care involves a partnership including the health care team, the child, and the family. Pediatric medicine now emphasizes the importance of information exchange among these groups. This paper discusses two models for communi...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-007-0061-9
更新日期:2007-11-01 00:00:00
abstract::This review briefly summarizes the results of previous systemic (chemotherapy) and local (surgery and radiotherapy) treatment attempted to date for malignant mesothelioma. The prospects for newer modalities, ie molecular and biologic therapies, are also highlighted, including results of both preclinical and early clin...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-002-0006-2
更新日期:2002-07-01 00:00:00
abstract::The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafe...
journal_title:Current oncology reports
pub_type: 杂志文章
doi:10.1007/s11912-013-0292-x
更新日期:2013-04-01 00:00:00
abstract::Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, mo...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-000-0108-7
更新日期:2000-11-01 00:00:00
abstract::Cyclin-dependent kinases (CDKs) and their related pathways represent some of the most attractive targets in the development of anticancer therapeutics. Among a variety of CDK inhibitors under development, flavopiridol, UCN-01, CYC202, and BMS-387032 are undergoing clinical evaluation based on evidence of preclinical a...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-004-0024-3
更新日期:2004-03-01 00:00:00
abstract:PURPOSE OF REVIEW:Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS:With the rise of novel therapeutic techniques and med...
journal_title:Current oncology reports
pub_type: 杂志文章,评审
doi:10.1007/s11912-019-0856-5
更新日期:2019-11-14 00:00:00